clinical trial · NCT05686356
A Pan-TB Regimen Targeting Host and Microbe
The Aurum Institute NPC·phase3·active not recruiting·n = 352
TuberculosisSutezolidN-acetyl cysteinePretomanidBedaquilineRifafour
brief summary
This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie, not requiring knowledge of RIF susceptibility. The regimen will test sutezolid at 2 dose levels, with the approved anti-TB drugs bedaquiline and pretomanid, in a phase 2c trial. It will also test whether the addition of N-acetylcysteine (NAC), a re-purposed host-directed WHO essential medicine, can protect the lung and liver against oxidative damage, preserve lung function, and accelerate the eradication of MTB infection by replenishing glutathione (GSH).
started
Jul 28, 2023
primary completion
Jan 1, 2026
completion
Jan 1, 2026
last updated
May 28, 2025
official title
A Novel 4-month Pan-TB Regimen Targeting Both Host and Microbe (panTB-HM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol